Literature DB >> 29726011

MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8.

Yalin Chen1, Li Bian2, Yingmei Zhang1.   

Abstract

OBJECTIVE: To investigate the relationship between miR-505 and RASSF8 as well as the effect of miR-505 on methotrexate (MTX) resistance of human colorectal cancer (CRC).
METHODS: Microarray was used to select differentially expressed miRNAs. QRT-PCR and western blot were performed to assess miR-505 and RASSF8 mRNA levels in MTX-sensitive and MTX-resistant CRC tissues and cells. Cell viability, propagation and apoptosis were confirmed by MTT, colony formation assays and flow cytometry. Transwell and wound healing assays were conducted on cancerous cells to determine cell metastasis. The target relationship between miR-505 and RASSF8 was validated using dual-luciferase reporter gene assay. KEY
FINDINGS: MiR-505 expression significantly increased in resistant tissues compared with sensitive tissues. Down-regulation of miR-505 expression weakened the proliferation ability of LS174T and LS174T/MTX cells, induced cell cycle arrest and apoptosis rate. RASSF8 was a target of miR-505 and overexpression of miR-505 down-regulated RASSF8 mRNA and protein expression. Overexpression of RASSF8 could affect the cycle of CRC cells, accelerate apoptosis as well as restrain migration and invasion. Moreover, miR-505 advanced MTX-induced LS174T cells migration and invasiveness as well as depressed LS174T/MTX cell apoptosis through the down-regulation of RASSF8.
CONCLUSION: MiR-505 mediated MTX resistance, propagation, cell cycle and metastasis by targeting RASSF8 in colorectal cancer.
© 2018 Royal Pharmaceutical Society.

Entities:  

Keywords:  zzm321990RASSF8zzm321990; colorectal cancer; methotrexate; miR-505

Mesh:

Substances:

Year:  2018        PMID: 29726011     DOI: 10.1111/jphp.12913

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  6 in total

Review 1.  Regulation of RASSF by non-coding RNAs in different cancers: RASSFs as masterminds of their own destiny as tumor suppressors and oncogenes.

Authors:  Ammad Ahmad Farooqi; Gulnara Kapanova; Abay Z Kussainov; Zaure Datkhayeva; Karlygash Raganina; Bolat N Sadykov
Journal:  Noncoding RNA Res       Date:  2022-05-13

2.  The long noncoding RNA CRAL reverses cisplatin resistance via the miR-505/CYLD/AKT axis in human gastric cancer cells.

Authors:  Zhangding Wang; Qiang Wang; Guifang Xu; Na Meng; Xinli Huang; Zerun Jiang; Chen Chen; Yan Zhang; Junjie Chen; Aiping Li; Nan Li; Xiaoping Zou; Jianwei Zhou; Qingqing Ding; Shouyu Wang
Journal:  RNA Biol       Date:  2020-01-07       Impact factor: 4.652

3.  MicroRNA-322 Regulates Self-renewal of Mouse Spermatogonial Stem Cells through Rassf8.

Authors:  Yinjuan Wang; Xiaoyong Li; Xiaowen Gong; Yongqiang Zhao; Ji Wu
Journal:  Int J Biol Sci       Date:  2019-03-01       Impact factor: 6.580

4.  microRNA-505 negatively regulates HMGB1 to suppress cell proliferation in renal cell carcinoma.

Authors:  Bing Zhong; Zhiqiang Qin; Hui Zhou; Fengming Yang; Ke Wei; Xi Jiang; Ruipeng Jia
Journal:  J Cell Physiol       Date:  2019-01-15       Impact factor: 6.384

5.  The long noncoding RNA DLGAP1-AS2 facilitates cholangiocarcinoma progression via miR-505 and GALNT10.

Authors:  Zhao Liu; Lili Pan; Xiaofang Yan; Xiuna Duan
Journal:  FEBS Open Bio       Date:  2020-12-31       Impact factor: 2.792

Review 6.  MicroRNA as a Potential Therapeutic Molecule in Cancer.

Authors:  Joanna Szczepanek; Monika Skorupa; Andrzej Tretyn
Journal:  Cells       Date:  2022-03-16       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.